After 1922.gov.tw comes online, I will turn off the reservation component of vaxx.tw, leaving up the translations of the vaccine target groups. I am so grateful for everyone's work over the past few weeks. Through your hard work, we: Translated the site into 5 different languages. ...
The Department of Veterans Affairs was the first federal agency to require health care employees to get vaccinated against COVID-19, and now it's expanding who will need to be vaccinated in order to keep their jobs. Veterans Affairs Secretary Denis McDonough announced on "CBS This Morning" ...
Vaxxinity, Inc. (Nasdaq: VAXX), today announced results from studies demonstrating the ability of UB-612, its COVID-19 vaccine candidate, to elicit a broad immune response against multiple variants of concern, and specifically ...
Vaxart's vaccine contains DNA instructions to make the spike protein, which enables the virus to enter human cells, as well as instructions to make the N protein, which is involved in other processes. Tucker said the inclusion of the N protein may make the vaccine retain its ability to ...
Vaxart began its Phase 2 COVID-19 oral vaccine trials in the US in October 2021. Data is expected in the first half of 2022. The study evaluated three different vaccine candidates: VXA-CoV2-1.1-S or ED90, based on the S protein from the SARS-Co...
Vaxxas Opens World-Class Manufacturing Facility To Produce Needle-Free Vaccine Patch June 6, 2023 Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP) June 6, 2023 Vaxxas Appoints...
Valneva has had a rocky couple of months. While European authorities recommended its non-mRNA Covid shot for primary vaccination in adults in late June, the …
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine c...
13价肺炎球菌多糖结合疫苗(13-valent pneumococcal polysaccharide conjugate vaccine,PCV13,用于6 周龄至5 岁婴幼儿和儿童,暂未获批成人适应证)。 3.接种建议 (1)建议接种:65岁以上风湿免疫病患者和18岁以上接受免疫抑制治疗的风湿免疫病患者均建议接种肺炎球菌疫苗,免疫程序按照疫苗说明书执行。
“Approved COVID-19 vaccines afford less protection against infection from new SARS-CoV-2 variants compared with the original parental strain against which they were developed. A broadly cross-reactive vaccine may be the most effective way to protect against cu...